Loading cancer entity…
Loading cancer entity…
Clinical trials
10,628 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,642)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06931613 | Autologous Hematopoietic Stem Cell Transplantation in Pediatric Relapsed or Refractory Hodgkin Lymphoma After Nivolumab Treatment | enrolling by invitation | Phase 2 | 20 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Apr 17, 2025 | clinicaltrials |
| NCT03500133 | Pediatric Hodgkin Lymphoma Treatment Trial With Low Cumulative Doses of Chemotherapy Agents and Reduced Radiation.(LHGALOP2017) | recruiting | Phase 4 | 500 | Hospital JP GarrahanOTHER_GOV | 1 |
| Apr 16, 2025 |
| clinicaltrials |
| NCT03952078 | A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma | active not recruiting | Phase 1 | 151 | Corvus Pharmaceuticals, Inc.INDUSTRY | 4 | Apr 16, 2025 | clinicaltrials |
| NCT04494503 | Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL | recruiting | Phase 1 / Phase 2 | 123 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Apr 16, 2025 | clinicaltrials |
| NCT05635162 | Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma(ZEBRA) | recruiting | Phase 2 | 50 | University College, LondonOTHER | 1 | Apr 16, 2025 | clinicaltrials |
| NCT06140966 | Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma | recruiting | Phase 2 | 54 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Apr 16, 2025 | clinicaltrials |
| NCT06918015 | Zanubrutinib Plus GCVP (Obinutuzumab, Cyclophosphamide, Vindesine, Prednisolone) in Previously Untreated Follicular Lymphoma | not yet recruiting | Phase 2 | 58 | Zhejiang Cancer HospitalOTHER | 1 | Apr 15, 2025 | clinicaltrials |
| NCT06925958 | A Clinical Trial Evaluating the Safety Tolerability, Radiation Absorption Dose, Distribution, PET Imaging and Histological Expression of 68Ga-NOTA-SCH001 in Patients With Multiple Myeloma | not yet recruiting | N/A | 15 | The First Affiliated Hospital of Soochow UniversityOTHER | 0 | Apr 13, 2025 | clinicaltrials |
| NCT02964858 | Radiation Dose Optimization in Diffuse Large B- Cell Lymphoma.(DOBL) | recruiting | N/A | 840 | Tata Memorial HospitalOTHER_GOV | 1 | Apr 11, 2025 | clinicaltrials |
| NCT06924424 | Aponermin, Pomalidomide, Dexamethasone for Patients With Relapsed/ Refractory Multiple Myeloma | active not recruiting | N/A | 105 | Peking University People's HospitalOTHER | 1 | Apr 11, 2025 | clinicaltrials |
| NCT03600441 | Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma(FORERUNNER) | active not recruiting | Phase 2 | 139 | Xynomic Pharmaceuticals, Inc.INDUSTRY | 3 | Apr 10, 2025 | clinicaltrials |
| NCT03934567 | A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma | active not recruiting | Phase 2 | 87 | Xynomic Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 10, 2025 | clinicaltrials |
| NCT03936153 | Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) | recruiting | Phase 2 | 170 | Xynomic Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 10, 2025 | clinicaltrials |
| NCT04024696 | A Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese Patients | active not recruiting | Phase 1 / Phase 2 | 12 | Xynomic Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 10, 2025 | clinicaltrials |
| NCT04300101 | Mixed Molecular Clinical Index (MMCI) in Diffuse Large B-cell Lymphoma (DLBCL)(MMCI) | recruiting | — | 300 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Apr 10, 2025 | clinicaltrials |
| NCT04891809 | Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged ≥70 Years) With NDMM | active not recruiting | Phase 2 | 198 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 3 | Apr 10, 2025 | clinicaltrials |
| NCT05945524 | Analysis of the Resistance and Sensitivity Mechanisms to Teclistamab by Focusing on Single Immune Cell Examination(ResisTec) | recruiting | N/A | 100 | University Hospital, ToulouseOTHER | 1 | Apr 10, 2025 | clinicaltrials |
| NCT06294652 | AGMT Austrian Lymphoma Registry | recruiting | — | 4,000 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 1 | Apr 10, 2025 | clinicaltrials |
| NCT06921044 | A Study of R-mini-MCOP in the Treatment of Elderly, Previously Untreated DLBCL | not yet recruiting | Phase 2 | 33 | Xiaohui HeOTHER | 0 | Apr 10, 2025 | clinicaltrials |
| NCT05259553 | Biomarkers in Multiple Myeloma(VESICOM) | recruiting | N/A | 70 | Centre Hospitalier Universitaire de Saint EtienneOTHER | 1 | Apr 9, 2025 | clinicaltrials |
| NCT06750965 | Multi-center Screening for Serum M Protein | not yet recruiting | — | 10,000 | Zhujiang HospitalOTHER | 0 | Apr 9, 2025 | clinicaltrials |
| NCT06918912 | Study of Loncastuximab Tesirine in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or High-Grade B-Cell Lymphoma (HGBCL) Following CAR-T Therapy Failure(LORELY) | recruiting | Phase 2 | 50 | Istituto Clinico HumanitasOTHER | 1 | Apr 9, 2025 | clinicaltrials |
| NCT06919679 | Phase II Trial of BrECADD in HIV-Positive Patients With Advanced-Stage Classical Hodgkin Lymphoma(BASTION) | not yet recruiting | Phase 2 | 35 | University of CologneOTHER | 0 | Apr 9, 2025 | clinicaltrials |
| NCT05702502 | Assessing the Presence of CT-DNA in Lymphoma Associated HLH | recruiting | — | 12 | Nottingham University Hospitals NHS TrustOTHER | 1 | Apr 8, 2025 | clinicaltrials |
| NCT05846880 | VitD3 Supplementation in Patients With Multiple Myeloma | recruiting | Early Phase 1 | 100 | Amany Keruakous, MD, MS.OTHER | 1 | Apr 8, 2025 | clinicaltrials |
| NCT06916416 | Phase II Trial of Anti-PD-1 Antibody Treatment and Radiotherapy in Early-stage Favorable Classic Hodgkin Lymphoma(PREFer) | not yet recruiting | Phase 2 | 50 | University of CologneOTHER | 0 | Apr 8, 2025 | clinicaltrials |
| NCT05686447 | Screening and Therapeutic Monitoring of Multiple Myeloma by MALDI-TOF MS Analysis | recruiting | — | 200 | Zhujiang HospitalOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT06045195 | Pembrolizumab in First-Line Treatment of Advanced-Stage Classical Hodgkin Lymphoma(Pembro-FLASH) | not yet recruiting | Phase 2 | 40 | University of CologneOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT06913179 | CAR-T Cell Therapy Combined With Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Multiple Myeloma(CAR-T-allo) | not yet recruiting | Phase 1 | 30 | Xuzhou Medical UniversityOTHER | 0 | Apr 6, 2025 | clinicaltrials |
| NCT06913192 | Efficacy of Sequential BCMA CAR-T Cell Therapy Following Autologous Hematopoietic Stem Cell Transplantation in Transplant-eligible Newly Diagnosed Multiple Myeloma(AUTO-CAR-T) | not yet recruiting | Phase 1 | 50 | Xuzhou Medical UniversityOTHER | 0 | Apr 6, 2025 | clinicaltrials |
| NCT06914037 | A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies(COURAGE) | recruiting | Phase 1 | 24 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT06911710 | The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors(CAR-T) | recruiting | Phase 1 / Phase 2 | 90 | Tianjin Medical University General HospitalOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT03376672 | Ixazomib Plus Lenalidomide Plus Dexamethasone for Newly Diagnosed Myeloma Patients | active not recruiting | Phase 2 | 120 | Raija SilvennoinenOTHER | 4 | Apr 3, 2025 | clinicaltrials |
| NCT03480334 | Abscopal Effect of Radiotherapy and Nivolumab in Relapsed Hodgkin Lymphoma After Anti-PD1 Therapy(AERN) | active not recruiting | Phase 2 | 26 | University of CologneOTHER | 1 | Apr 3, 2025 | clinicaltrials |
| NCT05530096 | Telo Genomics Technology to Detect & Profile Multiple Myeloma MRD(TELO - DMRD) | recruiting | — | 70 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 1 | Apr 3, 2025 | clinicaltrials |
| NCT06760039 | Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCL | recruiting | Phase 1 / Phase 2 | 112 | Sun Yat-sen UniversityOTHER | 1 | Apr 3, 2025 | clinicaltrials |
| NCT06880601 | Teclistamab Plus Autologous Lymphocyte Infusion (ALI) for the Treatment of R/R Multiple Myeloma(TALIM) | not yet recruiting | Phase 2 | 52 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 0 | Apr 3, 2025 | clinicaltrials |
| NCT06484829 | Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 144 | Chengdu Zenitar Biomedical Technology Co., LtdINDUSTRY | 1 | Apr 2, 2025 | clinicaltrials |
| NCT06788600 | Mechanistic Study of EBV mRNA Vaccine (WGc-043) in EBV-Positive Relapsed/Refractory Lymphoma(WGc-043) | not yet recruiting | — | 15 | Ruijin HospitalOTHER | 1 | Apr 2, 2025 | clinicaltrials |
| NCT06895291 | Whole Body MRI in Oncology(ONCO-MRI) | recruiting | — | 1,000 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Mar 30, 2025 | clinicaltrials |
| NCT06901999 | Methotrexate or Thiotepa Combined With R-CHOP and Orelabrutinib in CNSL Patients | not yet recruiting | Phase 2 | 23 | Ruijin HospitalOTHER | 0 | Mar 30, 2025 | clinicaltrials |
| NCT04392037 | Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone(ICON) | active not recruiting | Phase 2 | 60 | Amsterdam UMC, location VUmcOTHER | 1 | Mar 28, 2025 | clinicaltrials |
| NCT06895512 | A Study to Evaluate the Efficacy and Safety of HLX15-IV Versus DARZALEX® in Combination with Lenalidomide-Dexamethasone (Rd) in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma | not yet recruiting | Phase 3 | 386 | Shanghai Henlius BiotechINDUSTRY | 1 | Mar 26, 2025 | clinicaltrials |
| NCT06313957 | A Study of LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | recruiting | Phase 1 | 42 | Peking University Cancer Hospital & InstituteOTHER | 1 | Mar 25, 2025 | clinicaltrials |
| NCT06894693 | A Phase I Clinical Trial of RS001 in Patients with Relapsed/Refractory B-Cell Malignancies | not yet recruiting | Phase 1 | 13 | Guangdong Ruishun Biotech Co., LtdINDUSTRY | 0 | Mar 25, 2025 | clinicaltrials |
| NCT06891157 | Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes | recruiting | Phase 2 | 148 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Mar 24, 2025 | clinicaltrials |
| NCT04962126 | Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapy(FLUORO) | active not recruiting | Phase 2 | 15 | Olivia Newton-John Cancer Research InstituteOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT06888752 | LCAR-M61SQ in Treatment of Relapsed/Refractory Multiple Myeloma | not yet recruiting | N/A | 35 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 0 | Mar 21, 2025 | clinicaltrials |
| NCT06888856 | Multiple Myeloma is a Hematologic Malignancy Characterized by the Accumulation of Malignant Plasma Cells in the Bone Marrow. Despite Advances in Treatment, Many Patients Experience Disease Relapse. Bispecific Antibodies Offer an Innovative Therapeutic Approach, But Approximately 30%-40% of Patients(MMOMICS) | not yet recruiting | — | 200 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 0 | Mar 21, 2025 | clinicaltrials |
| NCT06890091 | Study of the Association Between Fatigue Experienced by Patients and the Specific Side Effects of CART Cells, During the First Month After Administration for Non-Hodgkin's Lymphoma(CAR-TIGUE) | not yet recruiting | — | 100 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Mar 21, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Apr 17, 2025source: clinicaltrials